Phosphate And Fibroblast Growth Factor 23 (FGF-23) In Early Chronic Kidney Disease – Their Importance In Bone Mineral Metabolism And As Cardiovascular Risk Factors.
Funder
National Health and Medical Research Council
Funding Amount
$140,949.00
Summary
In the chronic kidney disease (CKD) population, serum phosphate and fibroblast growth factor-23 (FGF-23), a phosphate regulating hormone, are strongly associated with mortality and cardiovascular disease (CVD). This thesis will examine phosphate homeostasis in clinical studies necessary to address this problem, as phosphate and FGF-23 are potential therapeutic targets.
Vitamin D And Chronic Kidney Disease: The Effects On Mineral Metabolism, Vascular Calcification And Transplant Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$103,582.00
Summary
Kidney disease is a major health issue in the community. Vitamin D deficiency has been associated with an increased burden of cardiovascular disease and mortality in these patients. Vitamin D also has been shown to have a significant role in modulating our immune system. This study aims to assess the potential of vitamin D therapy to reduce the burden of cardiovascular disease and its effects on the immune function of renal transplant recipients in the laboratory and clinical setting.
Improving Health Outcomes For Aboriginal And Torres Strait Islander Australians With Chronic Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$383,684.00
Summary
Based in Darwin, Dr Hughes’ research focuses on improving the health and wellbeing of Aboriginal and Torres Strait Islander peoples at risk of chronic kidney disease (CKD), and those with established Chronic and end-stage kidney disease. These studies focus on participants based in both community and hospital based populations. New areas of clinical research will be addressed, as well as health systems strengthening in both primary and tertiary care systems.
The Interaction Between Kidney Disease And Cardiovascular Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$44,013.00
Summary
People with chronic kidney disease have increased risk of cardiovascular events and mortality. Establishing predictors of these events can identify individuals most at risk and stratify therapy. Modifying risks reduces the progression of disease in people with chronic kidney disease. Risk prediction modelling has been done, but is not validated and requires clinical usability and application. This research aims to develop and validate risk prediction models and from them create clinician-friendl ....People with chronic kidney disease have increased risk of cardiovascular events and mortality. Establishing predictors of these events can identify individuals most at risk and stratify therapy. Modifying risks reduces the progression of disease in people with chronic kidney disease. Risk prediction modelling has been done, but is not validated and requires clinical usability and application. This research aims to develop and validate risk prediction models and from them create clinician-friendly interfaces.Read moreRead less
Serial NT-proBNP Monitoring For Predicting Major Cardiovascular Events In The Dialysis Population
Funder
National Health and Medical Research Council
Funding Amount
$288,548.00
Summary
Dialysis patients have a 50-100 fold increased risk of dying from heart disease caused by abnormal heart muscle structure and function. Current tests are unable to accurately identify patients at the highest risk. A test that accurately detects the early stages of heart injury is urgently needed. The aim of our research is to develop a monitoring guide using regular testing of a heart hormone (NT-proBNP) to identify high-risk dialysis patients early allowing treatment before a serious medical co ....Dialysis patients have a 50-100 fold increased risk of dying from heart disease caused by abnormal heart muscle structure and function. Current tests are unable to accurately identify patients at the highest risk. A test that accurately detects the early stages of heart injury is urgently needed. The aim of our research is to develop a monitoring guide using regular testing of a heart hormone (NT-proBNP) to identify high-risk dialysis patients early allowing treatment before a serious medical complication occurs.Read moreRead less
The Beta-blocker To LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study
Funder
National Health and Medical Research Council
Funding Amount
$597,811.00
Summary
The BLOCADE Feasibility Study aims to find out what is needed for a study to see if the drug carvedilol reduces heart disease events in people who need kidney dialysis. Carvedilol is widely used to treat the types of heart disease that are common in people on dialysis but the nature of dialysis may lead to more side effects or to less benefit. A Feasibility Study must be done first to properly plan a large study of carvedilol in people on dialysis that answers this important question.
IMPROVE-CKD Study: Impact Of A Phosphate Binder On Cardiovascular Disease In Chronic Kidney Disease.
Funder
National Health and Medical Research Council
Funding Amount
$1,596,698.00
Summary
Chronic kidney disease (CKD) is a significant health problem and is associated with an increased risk of cardiovascular (CV) disease. Vascular calcification and arterial stiffness (stiffening of the blood vessels and arteries) are very common in people with CKD, and are linked to increased death from CV events. This study aims to examine the ways in which treatment with a phosphate binder, Lanthanum Carbonate, may reduce vascular calcification and arterial stiffness to decrease CV events.